Trial Profile
Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 24 Oct 2023 Status changed from active, no longer recruiting to completed.
- 26 Sep 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.
- 11 Nov 2021 Status changed from recruiting to active, no longer recruiting.